Dr. Usman's Cardiology Notes

Management of Dyslipidemia 1. Risk Stratification (Foundation) Management is driven by overall cardiovascular risk rather than LDL alone Major risk categories: Established ASCVD (very high risk) Diabetes mellitus Severe hypercholesterolemia (LDL ≥190 mg/dL) Primary prevention based on risk calculators --- 2. Lifestyle Modification (First-line for all) Diet Reduce saturated & trans fats Increase fiber (fruits, vegetables, whole grains) Mediterranean/DASH-style diet Limit refined sugars Exercise ≥150 min/week moderate intensity Weight Target BMI <25 kg/m² Others Smoking cessation Limit alcohol --- 3. Pharmacologic Therapy A. Statins (First-line) ↓ LDL by 30–60% Stabilize plaques High-intensity statins Atorvastatin 40–80 mg Rosuvastatin 20–40 mg Indications ASCVD → high-intensity LDL ≥190 → high-intensity Diabetes (age 40–75) → moderate/high --- B. Non-Statin Therapies Ezetimibe Add if LDL target not achieved with statin PCSK9 inhibitors Alirocumab, Evolocumab For very high-risk or...

NOAC Antidotes: Reversal Strategies for Direct Oral Anticoagulants (DOACs) Introduction Non–vitamin K antagonist oral anticoagulants (NOACs), also known as DOACs, are widely used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism. Despite their favorable safety profile compared to warfarin, major bleeding and urgent procedural needs require rapid reversal strategies. --- Classification of NOACs Direct Thrombin Inhibitor Dabigatran Factor Xa Inhibitors Rivaroxaban Apixaban Edoxaban --- Specific Antidotes 1. Dabigatran Reversal Antidote: Idarucizumab Mechanism: Monoclonal antibody fragment that binds dabigatran with very high affinity Dose: 5 g IV (2 × 2.5 g boluses) Onset: Immediate Indications: Life-threatening bleeding Emergency surgery --- 2. Factor Xa Inhibitor Reversal Antidote: Andexanet alfa Mechanism: Recombinant modified factor Xa decoy protein Targets: Rivaroxaban, Apixaban (limited data for Edoxaban) Administration: Bolus + infusion (dose dep...

Imaging Assessment of Aortic Regurgitation (AR) -- Introduction Aortic regurgitation (AR) is characterized by diastolic backflow of blood from the aorta into the left ventricle (LV). Imaging plays a central role in diagnosis, quantification of severity, mechanism identification, and timing of intervention. --- 1. Transthoracic Echocardiography (TTE) – First-Line Modality Primary tool for evaluation. A. Mechanism of AR Leaflet pathology: prolapse, perforation, restriction Aortic root disease: dilation, dissection Vegetations (infective endocarditis) B. Qualitative Parameters Color Doppler jet width and extent Jet direction (eccentric vs central) Dense continuous-wave (CW) Doppler signal C. Semi-Quantitative Parameters Vena contracta width Mild: <0.3 cm Severe: ≥0.6 cm Pressure half-time (PHT) Severe AR: <200 ms D. Quantitative Parameters Regurgitant volume ≥60 mL → Severe Regurgitant fraction ≥50% → Severe Effective regurgitant orifice area (EROA) ≥0.3 cm² → Severe E. LV Assessmen...

Pulmonary Artery Systolic Pressure (PASP) Calculation on Echocardiography Introduction Pulmonary artery systolic pressure (PASP) is a key echocardiographic parameter used to assess pulmonary hemodynamics and screen for pulmonary hypertension. It is non-invasively estimated using Doppler interrogation of tricuspid regurgitation (TR). --- Principle PASP is derived from the pressure gradient between the right ventricle (RV) and right atrium (RA) during systole, using the modified Bernoulli equation. \Delta P = 4V^2 Where: ΔP = pressure gradient between RV and RA V = peak velocity of tricuspid regurgitation (m/s) --- PASP Formula PASP = 4V^2 + RAP Where: PASP = Pulmonary artery systolic pressure V = Peak TR velocity (m/s) RAP = Right atrial pressure (mmHg) --- Step-by-Step Calculation 1. Measure TR Velocity Use continuous-wave Doppler across tricuspid valve Align Doppler beam parallel to TR jet Record peak TR velocity (V) 2. Calculate Pressure Gradient Apply Bernoulli equation: ΔP = 4V² 3....

 Hypertrophic Cardiomyopathy (HCM) Definition Hypertrophic cardiomyopathy is a genetic cardiac disorder characterized by unexplained left ventricular hypertrophy (LVH), often asymmetric, in the absence of abnormal loading conditions such as hypertension or valvular disease. --- Etiology Autosomal dominant mutations (most common) Sarcomeric protein gene mutations: β-myosin heavy chain Myosin-binding protein C Troponin T/I --- Pathophysiology Myocyte hypertrophy and disarray Interstitial fibrosis Dynamic LVOT (left ventricular outflow tract) obstruction Diastolic dysfunction (impaired relaxation) Mitral valve systolic anterior motion (SAM) --- Types Asymmetric septal hypertrophy (ASH) – most common Concentric hypertrophy Apical HCM Mid-ventricular obstruction variant --- Clinical Features Often asymptomatic Dyspnea (most common) Chest pain (angina-like) Syncope or presyncope (especially exertional) Palpitations Sudden cardiac death (SCD), especially in young individuals/athletes --- ...

  Mitral Stenosis on Echocardiography – Concise Reporting Guide Introduction Mitral stenosis (MS) remains a clinically significant valvular lesion, especially in regions where rheumatic heart disease is prevalent. Echocardiography is the gold standard for diagnosis, severity assessment, and procedural planning. A structured, concise reporting style improves clarity, clinical decision-making, and reproducibility. --- Why Concise Reporting Matters Avoids ambiguity in severity grading Helps cardiologists quickly interpret hemodynamic impact Essential for intervention planning (e.g., PTMC) Improves communication between imaging and clinical teams --- Core Components of an Echo Report in Mitral Stenosis 1. Valve Morphology Focus on etiology and suitability for intervention: Leaflets: thickening, calcification, doming Mobility: restricted vs preserved Commissural fusion: present or absent Subvalvular apparatus: chordal thickening/shortening 👉 Suggestive of rheumatic MS: doming anterior ...

  Cardiac Resynchronization Therapy (CRT): Indications Introduction Cardiac Resynchronization Therapy (CRT) is an established device-based treatment for patients with heart failure and electrical dyssynchrony, particularly in the setting of prolonged QRS duration. It improves symptoms, reduces hospitalizations, and decreases mortality in appropriately selected patients. --- Pathophysiologic Basis Ventricular dyssynchrony (especially with LBBB) → inefficient LV contraction Reduced stroke volume and increased mitral regurgitation CRT restores coordinated ventricular contraction → improves cardiac output --- Core Indications (Guideline-Based) Strong Indications (Class I) CRT is recommended in patients with: Symptomatic heart failure (NYHA class II–IV despite optimal medical therapy) LVEF ≤35% Sinus rhythm Left bundle branch block (LBBB) morphology QRS duration ≥150 ms Key takeaway: 👉 Best responders = LBBB + wide QRS ≥150 ms --- Moderate Indications (Class IIa) CRT should be consider...